ZA97669B - Method of managing the chemotheraphy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains. - Google Patents

Method of managing the chemotheraphy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains.

Info

Publication number
ZA97669B
ZA97669B ZA9700669A ZA97669A ZA97669B ZA 97669 B ZA97669 B ZA 97669B ZA 9700669 A ZA9700669 A ZA 9700669A ZA 97669 A ZA97669 A ZA 97669A ZA 97669 B ZA97669 B ZA 97669B
Authority
ZA
South Africa
Prior art keywords
hiv
chimeric
inhibitor
managing
sensitivity
Prior art date
Application number
ZA9700669A
Other languages
English (en)
Inventor
Marie-Pierre De Bethune
Kurt Hertogs
Rudi Pauwels
Original Assignee
Birco N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Birco N V filed Critical Birco N V
Publication of ZA97669B publication Critical patent/ZA97669B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA9700669A 1996-01-26 1997-12-27 Method of managing the chemotheraphy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains. ZA97669B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96200175 1996-01-26

Publications (1)

Publication Number Publication Date
ZA97669B true ZA97669B (en) 1998-06-25

Family

ID=8223611

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9700669A ZA97669B (en) 1996-01-26 1997-12-27 Method of managing the chemotheraphy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains.

Country Status (21)

Country Link
US (3) US6221578B1 (fr)
EP (1) EP0877937B1 (fr)
KR (1) KR100495690B1 (fr)
CN (2) CN1209875A (fr)
AT (1) ATE217971T1 (fr)
AU (1) AU717755B2 (fr)
BG (1) BG102710A (fr)
BR (1) BR9707204A (fr)
CZ (1) CZ292899B6 (fr)
DE (1) DE69712731T2 (fr)
ES (1) ES2177922T3 (fr)
HU (1) HU226203B1 (fr)
IL (1) IL125442A (fr)
IS (1) IS4799A (fr)
NO (1) NO321329B1 (fr)
NZ (1) NZ325912A (fr)
PL (1) PL186473B1 (fr)
SK (1) SK283878B6 (fr)
TR (1) TR199801443T2 (fr)
WO (1) WO1997027480A1 (fr)
ZA (1) ZA97669B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT810209E (pt) 1992-08-25 2002-09-30 Searle & Co Hidroxietilamino-sulfonamidas de alfa- e beta-aminoacidos uteis como inibidores de protease retroviral
US20030220276A1 (en) * 1995-05-16 2003-11-27 Opendra Narayan HIV vaccine and method of use
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US20070010471A1 (en) * 1997-05-02 2007-01-11 Opendra Narayan HIV DNA vaccine
CA2298102A1 (fr) * 1997-07-30 1999-02-11 Virologic, Inc. Compositions et procedes permettant de determiner la sensibilite et la resistance vis-a-vis de medicaments antiviraux, et criblage de medicaments antiviraux
CN1204266C (zh) * 1998-05-26 2005-06-01 病毒科学公司 监控非核苷类逆转录酶抑制剂抗逆转录病毒治疗的途径与方法
ATE302287T1 (de) 1999-05-28 2005-09-15 Virco Nv Neue mutationsprofile der hiv-1 reverse transcriptase in verbindung mit phänotypischem medikamentresistenz
US6800437B1 (en) 1999-08-06 2004-10-05 Tibotec Bvba Method of monitoring a biological system by labeling with an apo metal binding protein
EP1109019A1 (fr) * 1999-12-15 2001-06-20 BioStrands S.r.l. Procédé d'évaluation de la sensibilité de variantes virales HIV à des agents inhibiteurs de la protéase virale
AU2001233513A1 (en) * 2000-02-04 2001-08-14 K.U. Leuven Research And Development Hiv-1 resistance assay
GB0009374D0 (en) * 2000-04-14 2000-05-31 Glaxo Group Ltd Phenotyping assay and reagents therefor
JP5156163B2 (ja) * 2000-04-18 2013-03-06 ビルコ・ビーブイビーエイ 薬剤耐性の測定方法
US6800463B1 (en) * 2000-04-20 2004-10-05 Virco Bvba Method for mutation detection in HIV-1 using pol sequencing
WO2001081624A1 (fr) * 2000-04-20 2001-11-01 Virco Bvba Procede de detection de mutation dans des hiv au moyen de sequençage pol
US6582901B2 (en) 2000-04-26 2003-06-24 Bruce K. Patterson Cell specific anti-viral drug susceptibility test using tagged permissive target cells
US7058616B1 (en) 2000-06-08 2006-06-06 Virco Bvba Method and system for predicting resistance of a disease to a therapeutic agent using a neural network
EP1292712A4 (fr) * 2000-06-12 2005-04-20 Virologic Inc Systemes et procedes pour le controle de therapie antiretrovirale et l'orientation des decisions therapeutiques dans le traitement du vih/sida
US6582920B2 (en) * 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
AU1234402A (en) * 2000-10-20 2002-04-29 Virco Nv Establishment of biological cut-off values for predicting resistance to therapy
AU2631602A (en) * 2000-10-20 2002-04-29 Virco Nv New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
US7306901B2 (en) 2001-08-08 2007-12-11 Tibotec Pharmaceuticals, Ltd. Methods and means for assessing HIV envelope inhibitor therapy
US6958211B2 (en) * 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
ATE389029T1 (de) 2001-11-08 2008-03-15 Tibotec Pharm Ltd Protease assay zur kontrolle medikamentöser therapie
WO2004003223A2 (fr) * 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. Nouveaux profils mutationnels dans une transcriptase inverse du vih-1 correles a une resistance phenotypique aux medicaments
CA2490862A1 (fr) * 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. Nouveaux profils mutationnels dans une protease du vih-1 correles a une resistance phenotypique aux medicaments
JP5213228B2 (ja) * 2004-03-02 2013-06-19 ビルコ・ビーブイビーエイ 臨床的カット−オフ値の推測
US8673551B2 (en) 2005-12-07 2014-03-18 Speedx Pty Ltd. Methods, plasmid vectors and primers for assessing HIV viral fitness
US20100009341A1 (en) * 2006-04-14 2010-01-14 Inky Paul Madeleine De Baere Methods and means for assessing hiv gag/protease inhibitor therapy
EP2162745A1 (fr) 2007-05-25 2010-03-17 Tibotec Pharmaceuticals Nouveau profil mutationnel dans un site de clivage du gag du vih-1 corrélé à une résistance phénotypique aux médicaments
ES2546190T3 (es) 2008-10-06 2015-09-21 Janssen Diagnostics Bvba Método para determinar mutaciones de resistencia a fármacos en cualquiera de las regiones de proteína no estructural NS3 a NS5B del virus de la hepatitis C (HCV) para los genotipos 1 a 6
EP2430181A1 (fr) * 2009-05-12 2012-03-21 Virco BVBA Surveillance de la résistance au vih-1-c
CN107085093B (zh) * 2017-03-24 2019-06-21 西藏诺迪康药业股份有限公司 重组人白细胞介素1受体拮抗剂滴眼液生物学活性的检测方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875396A (en) 1973-11-12 1975-04-01 Illuminite Corp Illuminated clipboard
US4675147A (en) * 1983-04-06 1987-06-23 Westinghouse Electic Corp. Generating an integrated graphic display of the safety status of a complex process plant
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
IL94482A (en) 1989-05-25 2003-09-17 Univ Duke Transdominant repressor mutant of retroviral protein, dna encoding the protein and process for their preparation and use thereof
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
JPH05148202A (ja) * 1991-04-10 1993-06-15 Tsumura & Co 新規な化合物およびその医薬としての用途
AU4248593A (en) 1992-05-14 1993-12-13 Mark Holodniy Polymerase chain reaction assays for monitoring antiviral therapy
US5733720A (en) 1992-06-18 1998-03-31 Washington University Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor
JP3456703B2 (ja) 1992-07-06 2003-10-14 プレジデント アンド フェローズ オブ ハーバード カレッジ リポーター遺伝子に融合した細菌のストレスプロモーターを用いる毒性を測定するための方法および診断用キット
US5344846A (en) 1992-12-30 1994-09-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells
US5591579A (en) 1993-12-21 1997-01-07 Washington University Indicator cell line for detecting RNA viruses and method therefor
US6063562A (en) 1994-09-16 2000-05-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
CA2232086A1 (fr) 1995-09-15 1997-04-03 Samir Chachoua Procede d'identification et d'utilisation therapeutique d'organismes, d'elements et de forces associes a une maladie
US5885806A (en) * 1995-11-28 1999-03-23 The Johns Hopkins University School Of Medicine Methods to prepare conditionally replicating viral vectors
US5837464A (en) 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
AP9801360A0 (en) 1996-01-29 1998-12-31 Virologic Incorporated Compositions and methods ofr determining anti-viral drug susceptibility and resistance and anti-viral drug screening.
US5945276A (en) 1996-04-10 1999-08-31 Signal Pharmaceuticals, Inc. Reporter cell line system for detecting cytomegalovirus and identifying modulators of viral gene expression
US5939253A (en) 1996-04-26 1999-08-17 Diagnostic Hybrids, Inc. Compositions and methods for detecting viral infection
ATE354089T1 (de) 1997-04-07 2007-03-15 Fisher Bioimage Aps Ein verfahren zum screenen von substanzen hinsichtlich ihres effekts auf camp spiegel basierend auf intrazellulärer translokation von pka
US6365347B1 (en) 1997-04-11 2002-04-02 The Regents Of The University Of California Method for identifying disruptors of biological pathways using genetic selection
WO1998059074A1 (fr) 1997-06-23 1998-12-30 Emory University Virus de l'immunodeficience humaine induisant le sida chez un primate non humain
US5976813A (en) 1997-12-12 1999-11-02 Abbott Laboratories Continuous format high throughput screening

Also Published As

Publication number Publication date
WO1997027480A1 (fr) 1997-07-31
BR9707204A (pt) 1999-12-28
CN1209875A (zh) 1999-03-03
SK100298A3 (en) 1999-02-11
EP0877937A1 (fr) 1998-11-18
BG102710A (en) 1999-03-31
US6528251B2 (en) 2003-03-04
NO983300D0 (no) 1998-07-16
TR199801443T2 (xx) 1998-10-21
US20020042679A1 (en) 2002-04-11
IL125442A (en) 2002-03-10
US20030152917A1 (en) 2003-08-14
CZ292899B6 (cs) 2003-12-17
HUP9902618A3 (en) 2001-04-28
PL328069A1 (en) 1999-01-04
IL125442A0 (en) 1999-03-12
ES2177922T3 (es) 2002-12-16
DE69712731D1 (de) 2002-06-27
AU1316897A (en) 1997-08-20
HU226203B1 (en) 2008-06-30
ATE217971T1 (de) 2002-06-15
NZ325912A (en) 1999-01-28
SK283878B6 (sk) 2004-04-06
KR100495690B1 (ko) 2005-11-08
EP0877937B1 (fr) 2002-05-22
HUP9902618A2 (hu) 1999-12-28
IS4799A (is) 1998-07-20
AU717755B2 (en) 2000-03-30
DE69712731T2 (de) 2003-02-06
CN1991365A (zh) 2007-07-04
NO983300L (no) 1998-09-25
US6221578B1 (en) 2001-04-24
NO321329B1 (no) 2006-04-24
KR19990082027A (ko) 1999-11-15
PL186473B1 (pl) 2004-01-30
CZ233598A3 (cs) 1999-06-16

Similar Documents

Publication Publication Date Title
ZA97669B (en) Method of managing the chemotheraphy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains.
Nguyen et al. CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity
Gornalusse et al. Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor
Roos et al. Primate jumping genes elucidate strepsirrhine phylogeny
Billerbeck et al. Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties
Moens et al. Chromosome number of a small protist: accurate determination
Jankowski et al. Meiotic instability of CAG repeat tracts occurs by double-strand break repair in yeast
Bsat et al. Differential pathogenic Th17 profile in mesenteric lymph nodes of Crohn's disease and ulcerative colitis patients
Halnon et al. Immune dysregulation after cardiothoracic surgery and incidental thymectomy: maintenance of regulatory T cells despite impaired thymopoiesis
Mostowy et al. The role of recombination for the coevolutionary dynamics of HIV and the immune response
Sun et al. A transcriptional signature of IL-2 expanded natural killer cells predicts more favorable prognosis in bladder cancer
van den Ham et al. From the two-dimensional Th1 and Th2 phenotypes to high-dimensional models for gene regulation
GR3017271T3 (en) Double-stranded RNA correction of RNase L deficiency.
ATE404048T1 (de) Apparat zur gewichtsregistrierung
Huot et al. Role of NKG2a/c+ CD8+ T cells in pathogenic versus non-pathogenic SIV infections
Heywood Genetic correlates of edaphic differentiation and endemism in Gaillardia.
Chen et al. Methods taught in dental schools for determining the posterior palatal seal region.
PT880594E (pt) Vector retroviral e sua utilizacao em terapia genica
Hutchinson Workshop summary: DNA strand break repair in eukaryotes
Picton et al. Reduced CCR5 Expression and Immune Quiescence in Black South African HIV-1 Controllers
Takashima et al. Case report: BMPR2-targeted MinION sequencing as a tool for genetic analysis in patients with pulmonary arterial hypertension
Bianchi et al. Suppression by Allogeneic-Specific Regulatory T Cells Is Dependent on the Degree of HLA Compatibility
CA2244735A1 (fr) Procede pour gerer la chimiotherapie de patients seropositifs vih sur la base de la sensibilite medicamenteuse phenotypique de souches humaines du vih
Venken et al. Reduced number of blood circulating foxp3+ CD25highCD4+ regulatory T cells and a decreased foxp3 expression at the single-cell level in patients with relapsing-remitting multiple sclerosis
Johnson et al. A Review of Audiometry Results in Offshore Workers in the Brent Field